The 17 World’s Biggest Pharmaceutical Corporations in 2024

 

The 17 World’s Biggest Pharmaceutical Corporations–There are 17 World’s Biggest Pharmaceutical Corporations in 2024 and this data is obtained from the Annual reports of each corporation in 2024. Commonly, pharmaceutical corporations or drug corporations are commercial corporations that focus on researching, developing, and distributing drugs, especially in terms of health problems. They can manufacture generic drugs, branded drugs, medical devices, health supplements, and various health products.

In terms of health, many of us as humans still depend on these corporations. Of course, of all the pharmaceutical corporations scattered around the world, only a few corporations are able to become the leader of the world’s drug and supplement business with the various brands that exist today. Here are the 17 World’s Biggest Pharmaceutical Corporations Based on Annual Report Data for each corporation in 2024. This ranking order is based on the amount of profit/ net income obtained by each corporation in 2024.

 

Ranking Table of 17 World’s Biggest Pharmaceutical Corporations in 2024 Based on Net Income

Rank	Name of Pharmaceutical Corporations	Total Revenue	Total Revenue	Net Income	Net Income
		Origin Currency	in US Dollar (USD)	Origin Currency	in US Dollar (USD)
1	Novo Nordisk	DKK 290 billion	USD 43.5 billion	DKK 100 billion	USD 15 billion
2	Johnson & Johnson	USD 88.8 billion	USD 88.8 billion	USD 14 billion	USD 14 billion
3	Abbott Laboratories	USD 41.9 billion	USD 41.9 billion	USD 13.4 billion	USD 13.4 billion
4	Novartis	USD 50.3 billion	USD 50.3 billion	USD 11.9 billion	USD 11.9 billion
5	Hoffman-La Roche	CHF 62.3 billion	USD 76 billion	CHF 9.1 billion	USD 11.1 billion
6	Eli Lilly	USD 45 billion	USD 45 billion	USD 10.5 billion	USD 10.5 billion
7	Pfizer	USD 63.2 billion	USD 63.2 billion	USD 8 billion	USD 8 billion
8	Astrazeneca	USD 54 billion	USD 54 billion	USD 7 billion	USD 7 billion
9	Sanofi	EUR 41 billion	USD 45.5 billion	EUR 5.6 billion	USD 6.2 billion
10	AbbVie	USD 56.3 billion	USD 56.3 billion	USD 4.28 billion	USD 4.28 billion
11	Amgen Inc	USD 33.4 billion	USD 33.4 billion	USD 4 billion	USD 4 billion
12	GlaxoSmithKline	GBP 31.3 billion	USD 42.2 billion	GBP 2.9 billion	USD 3.9 billion
13	Merck & co	USD 21.1 billion	USD 21.1 billion	USD 2.7 billion	USD 2.7 billion
14	Takeda Pharmaceuticals	JPY 4,581 billion	USD 32 billion	JPY 107 billion	USD 0.75 billion
15	Gilead Sciences	USD 28.7 billion	USD 28.7 billion	USD 0.48 billion	USD 0.48 billion
16	Bayer	EUR 46.6 billion	USD 51.7 billion	(EUR -2.5 billion)	(USD -2.7 billion)
17	Bristol Myers Squibb	USD 48.3 billion	USD 48.3 billion	(USD -8.9 billion)	(USD -8.9 billion)
Source: Annual Report, 2024
Origin Currency: Currency that Officially Used in Annual Report 2024
US Dollar Currency: Converted Currency from Origin Currency to US Dollar
Currency Rate:
1 Swiss Franc (CHF) = 1.22 US Dollar (USD)
1 Euro= 1.11 US Dollar (USD)
1 Poundsterling (GBP) = 1.35 US Dollar (USD)
1 Danish Krone (DKK) = 0.15 US Dollar (USD)
1 Japanese Yen (JPY) = 0.0070 US Dollar (USD)

  

In addition to the income and profit performance obtained by each corporation, there is also a description related to the condition of the corporation’s total assets and total liabilities obtained from the corporation’s balance sheet of each corporation. The following is a description of the corporation’s assets and debts. Additional data related to the condition of assets and debts of the 17 world’s largest pharmaceutical corporations in 2024.

 

Table of Total Assets and Liabilities of 17 World’s Biggest Pharmaceutical Corporations in 2024

 

Rank	Name of Pharmaceutical Corporations	Total Assets	Total Assets	Total Liabilities	Total Liabilities
		Origin Currency	in US Dollar (USD)	Origin Currency	in US Dollar (USD)
1	Pfizer	USD 213.3 billion	USD 213.3 billion	USD 124.8 billion	USD 124.8 billion
2	Johnson & Johnson	USD 180.1 billion	USD 180.1 billion	USD 108.6 billion	USD 108.6 billion
3	Sanofi	EUR 132.7 billion	USD 147.2 billion	EUR 54.8 billion	USD 60.8 billion
4	AbbVie	USD 135.1 billion	USD 135.1 billion	USD 131.7 billion	USD 131.7 billion
5	Hoffman-La Roche	CHF 101.8 billion	USD 124.1 billion	CHF 65.6 billion	USD 80 billion
6	Bayer	EUR 110.8 billion	USD 123 billion	EUR 78.7 billion	USD 87.3 billion
7	Astrazeneca	USD 104 billion	USD 104 billion	USD 63.1 billion	USD 63.1 billion
8	Novartis	USD 102.2 billion	USD 102.2 billion	USD 58.1 billion	USD 58.1 billion
9	Takeda Pharmaceuticals	JPY 14,248 billion	USD 99.7 billion	JPY 7,312 billion	USD 55.1 billion
10	Bristol Myers Squibb	USD 92.6 billion	USD 92.6 billion	USD 76.2 billion	USD 76.2 billion
11	Amgen Inc	USD 91.8 billion	USD 91.8 billion	USD 85.9 billion	USD 85.9 billion
12	Abbott Laboratories	USD 81.4 billion	USD 81.4 billion	USD 33.5 billion	USD 33.5 billion
13	GlaxoSmithKline	GBP 59.4 billion	USD 80.2 billion	GBP 46.3 billion	USD 62.5 billion
14	Eli Lilly	USD 78.7 billion	USD 78.7 billion	USD 64.4 billion	USD 64.4 billion
15	Novo Nordisk	DKK 465 billion	USD 69.7 billion	DKK 322 billion	USD 48.3 billion
16	Gilead Sciences	USD 58.9 billion	USD 58.9 billion	USD 39.7 billion	USD 39.7 billion
17	Merk & co	USD 51.5 billion	USD 51.5 billion	USD 21.5 billion	USD 21.5 billion
Source: Annual Report, 2024
Origin Currency: Currency that Officially Used in Annual Report 2024
US Dollar Currency: Converted Currency from Origin Currency to US Dollar
Currency Rate:
1 Swiss Franc (CHF) = 1.22 US Dollar (USD)
1 Euro= 1.11 US Dollar (USD)
1 Poundsterling (GBP) = 1.35 US Dollar (USD)
1 Danish Krone (DKK) = 0.15 US Dollar (USD)
1 Japanese Yen (JPY) = 0.0070 US Dollar (USD)

 

---

 

Brief Description of 17 World’s Biggest Pharmaceutical Corporations in 2024

 

1. Hoffman-La Roche

 

Founded in 1896 by Fritz Hoffmann-La Roche, F. Hoffmann-La Roche AG is the world’s biggest pharmaceutical corporation in 2020. This corporation has a main office in Bassel, Switzerland. Initially, the corporation produced a variety of multivitamin products and in 1934, it became the first to mass-produce synthetic vitamin C, under the brand name Redoxon but it has been owned by Bayer. Specifically, Hoffman-La Roche focussed on Pharmaceuticals and Diagnostics activities, Roche Pharmaceuticals focused on finding new medicines and diagnostics that help patients live longer, better lives and evolve the practice of medicine. Meanwhile, Roche Diagnostics provides tools that prevent diseases from being diagnosed and monitored.

Commonly, as one of the world’s biggest pharmaceutical corporations, Roche has some top-selling pharmaceuticals products , namely Ocrevus (Neurology), Hemlibra (Haemophilia A), Perjeta (Oncology), Tecentriq (Oncology), Actemra/RoActemra (Immunology), Vabysmo (Ophthalmology), Xolair (Immunology), Kadcyla (Oncology), MabThera/Rituxan (Oncology/Immunology), and Herceptin (Oncology) with total selling around CHF 6.3 billion, CHF 4.1 billion, CHF 3.7 billion, CHF 3.7 billion, CHF 2.6 billion, CHF 2.3 billion, CHF 2.1 billion, CHF 1.9 billion, CHF 1.63 billion, and CHF 1.62 billion, respectively.

Financially, during 2024, the Hoffman-La Roche earned revenues of CHF 62.3 billion or equivalent to USD 76 billion with a net income of CHF 9.1 billion or equivalent to USD 11.1 billion. In terms of financial position, according to its balance sheet, Hoffman-La Roche has total assets of USD 213.3 billion with total liabilities of around USD 124.8 billion.

 

2. Johnson & Johnson

Johnson & Johnson (J&J) is one the world’s biggest pharmaceutical corporations in 2023 from the United States. Historically, this corporation was founded in 1886 in New Brunswick, New Jersey, the United States of America by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. Along with the development of time and business progression, many healthcare products produced by this corporation have been marketed in various parts of the world.

As of 2023, the corporation’s operations include approximately 250 subsidiaries operating in 60 countries with products sold in more than 175 countries and have approximately 131,900 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Operationally, Johnson&Johnson is now organized into two business segments, namely Innovative Medicine and MedTech.

In addition, in medicine segments, Johnson&Johnson has the Corporation’s key pharmaceutical products, namely STELARA (ustekinumab) accounted for approximately 12.8% of the Corporation’s total revenues for fiscal year of 2023, followed by DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 11.4% of the Corporation’s total revenues in 2023. In addition, a variety of healthcare products produced by Johnson-Johnson such as Clean and Clear, Listerine, Johnson Baby Powder, Mylanta, Visine eye drops. Regarding the Covid pandemic, this corporation is one of the producers and makers of the Covid-19 vaccine. 

Financially in 2024, according to its annual report, Johnson & Johnson successfully earned total revenues of USD 88.8 billion with a net income of USD 14 billion. In terms of financial position, total assets of Johnson & Johnson USD 180.1 billion and total liabilities reaching USD 108.6 billion.          

 

3. Sanofi

 

Founded in 1973, Sanofi S.A is one of the world’s biggest pharmaceutical corporations in the world by 2023. This corporation has its main office in Paris, France. In 2004, Sanofi-Synthélabo merged with Aventis and changed its name to Sanofi-Aventis. However, the corporation later changed its name back to Sanofi in May 2011. Some of Sanofi’s medicinal products include platogrix, Amaryl, Lantus Solostar, and Toplexil. Commonly, sanofi has engaged in  research and development, manufacturing, and marketing of pharmacological products, focussing in Immunology Research and development (R&D), Neurology R&D, Oncology R&D, Rare Blood Disorders R&D, Rare Diseases R&D and Vaccines R&D.

Financially, in 2024, this Sanofi successfully earned total revenues of EUR 41 billion or equivalent to USD 45.5 billion and successfully gained a net income of EUR 5.6 billion or equivalent to USD 6.2 billion.

 

4. Pfizer

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City. Founded in 1849 in New York City by Charles Pfizer and Charles F. Erhart, the corporation has grown rapidly to become one of the biggest pharmaceutical corporations in the world. In 2024, Pfizer successfully earned total revenues of USD 63.2 billion and successfully gained a net income of USD 8 billion. In terms of financial position in 2024, Pfizer has total assets of around USD 213.3 billion and total liabilities of around USD 124.8 billion.      

Commonly, some of the famous products from Pfizer are Viagra (one of the phenomenal ones), Lipitor, Combantrin worm medicine. In relation to the impact of the COVID-19 pandemic, this corporation has also issued a Covid-19 vaccine and has been distributed in various countries around the world.

Along with business development, Pfizer has ten manufacturing sites and two distribution centers in Andover (MA), Franklin (OH), Kalamazoo (MI), MCPherson (KS), Middleton (WI), Pearl River (NY), Rochester (MI), Rocky Mount (NC), and Sanford (NC). In addition, Some of the Pfizer products include Oncology, Primary care, and specialty care. Oncology (Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak). Meanwhile, Primary Care including Internal medicine (Eliquis, the Premarin family and BMP2), Migraine (Nurtec ODT/Vydura and Zavzpret), Vaccines (Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba), Treatment for COVID-19 (Paxlovid), Detection of COVID-19 and influenza (Lucira by Pfizer). In addition, Specialty Care including Inflammation & immunology (Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo and Velsipity), Rare disease (the Vyndaqel family, Genotropin, BeneFIX, Oxbryta, Somavert and Ngenla), Hospital (Sulperazon, Zavicefta, Zithromax, Medrol and Panzyga).

 

5.GlaxoSmithKline

GlaxoSmithKline plc (GSK) is one of the world’s biggest pharmaceutical corporations originating in the UK. The corporation’s head office is in London, England. Founded in 2000, through the merger of Glaxo Wellcome and SmithKline Beecham, the corporation has grown rapidly and has become one of the biggest pharmaceutical corporations in the world alongside Pfizer, Novartis, Roche, Sanofi, and Merck & Co.  

Some of the products sold, namely Sensodyne toothpaste, and the headache reliever Panadol are some of the other products. As of 2024, GlaxoSmithKline (GSK) has Commercial operations in manufacturing Specialty Medicines, General Medicine, and Vaccines. Specifically, Specialty Medicines of GlaxoSmithKline’s products are Dovato (HIV treatment), Nucala (Respiratory eosinophil-driven diseases), Triumeq (HIV treatment), Tivicay (HIV treatment), Benlysta (Lupus and lupus nephritis), Cabenuva (HIV treatment), Juluca (HIV treatment), Zejula (Ovarian cancer), Jemperli (Endometrial cancer),  Rukobia (HIV treatment), Xevudy (COVID-19 treatment), Blenrep (Blood cancer – multiple myeloma), Ojjaara/Omjjara (Myelofibrosis), and Jesduvroq/Duvroq Anaemia due to chronic kidney disease (CKD). In addition, the General Medicine of GlaxoSmithKline (GSK) includes Trelegy Ellipta (COPD, asthma), Seretide/Advair (Asthma, COPD), Relvar/Breo Ellipta (Asthma, COPD), Ventolin (Asthma, COPD),Augmentin (Common bacterial infections), Anoro Ellipta (COPD), Avodart & Duodart  (Benign prostatic hyperplasia (BPH), Avamys/Veramyst (Allergic rhinitis), and Dermovate, Betnovate, Cutivate, Eumovate (Inflammatory skin conditions).

Furthermore, the vaccines produced by GlaxoSmithKline (GSK) are Shingrix (Herpes zoster (shingles)), Arexvy (RSV), Bexsero (Meningitis group B), Boostrix (Diphtheria, tetanus, acellular pertussis booster), Rotarix (Rotavirus), Fluarix, FluLaval (Seasonal influenza), Infanrix, Pediarix (Diphtheria, tetanus, pertussis, polio, hepatitis B, haemophilus influenza type B), Engerix, Twinrix, Havrix (Hepatitis), Menveo (Meningitis group A, C, W and Y), Synflorix (Invasive disease, pneumonia, acute otitis media), Priorix, Priorix Tetra, Varilrix (Measles, mumps, rubella and chickenpox), and Cervarix (Human papillomavirus).

In 2024, based on the corporation’s 2024 annual report, the GlaxoSmithKline successfully earned total revenue of GBP 31.3 billion or equivalent to USD 42.2 billion, with a net income of GBP 2.9 billion or equivalent to USD 3.9 billion. In terms of financial position, GlaxoSmithKline has total assets of around GBP 59.4 billion or equivalent to USD 80.2 billion with total liabilities of GBP 46.3 billion or equivalent to USD 62.5 billion.

 

6. Novartis

 

Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland and Novartis has employed 76,057 of employees as of December 31, 2023. This corporation is one of the largest pharmaceutical corporations in the world which was founded in December 2000 in London, England. Along with business development, Sanovi has sold its medicine products in approximately 130 countries around the world.  Basically, some of the novartis’s medicines products in treating different treatments ,namely Cardiovascular, renal and metabolic ( Entresto, Leqvio (inclisiran),  Immunology (Cosentyx (secukinumab), Xolair (omalizumab), Ilaris (canakinumab)), Neuroscience (Kesimpta (ofatumumab), Zolgensma (onasemnogene abeparvovec)), Oncology (Promacta/Revolade (eltrombopag), Kisqali (ribociclib), Tafinlar + Mekinist (dabrafenib + trametinib), Tasigna (nilotinib), Jakavi (ruxolitinib), Pluvicto (lutetium (177Lu) vipivotide tetraxetan), Lutathera (lutetium Lu 177 dotatate/lutetium (177Lu) oxodotreotide)).

Financially, in 2024, according to its annual report, Novartis International successfully earned total revenues of USD 50.3 billion with a net net income that reached USD 11.9 billion. In terms of financial position, Novartis International has total assets of around USD 102.2 billion and total liabilities of around USD 58.1 billion.          

 

7. Merck & co

Merck & Co., Inc. or Merck Sharp & Dohme (MSD) is an American multinational pharmaceutical corporation headquartered in Kenilworth, New Jersey. The founders of this corporation are Theodore Weicker and George Merck.

In pharmaceutical industries, Merck & Co., Inc has some popular medicine products. These are Keytruda with sales of $ 25 billion in 2023, Gardasil/Gardasil 9 ($ 8.8 billion), Januvia/Janumet ($ 3.3 billion), ProQuad/M-M-R II/Varivax  ($ 2.3 billion), Bridion ($ 1.8 billion), Lagevrio ( $ 1.4 billion), Lynparza ( $1.1 billion), Lenvima ($ 960 million), RotaTeq ($ 769 million), and Vaxneuvance ($ 665 million).

Financially, in 2024, this Merck & Co successfully earned total revenues of USD 21.1 billion with a net income that reached USD 2.7 billion. In terms of financial position, the total assets of Merck & Co reached USD 51.5 billion and total liabilities of around USD 21.5 billion.

 

8. AbbVie

AbbVie is a pharmaceutical corporation that has its main office in North Chicago, Illinois, the United States of America which was founded in 2013. Actually, Abbvie was formed due to the divestment of Abbott Laboratories which used to be one with Abbott Laboratories.

Commonly, AbbVie has some different medicinal products for different diseases and cases. These  AbbVie’s portfolio of products includes Immunology products (Humira (adalimumab), Skyrizi (risankizumab)), Oncology products (Imbruvica (ibruti nib), Venclexta (venetoclax), Epkinly (epcoriti mab), Elahere (mirvetuximab soravtansine-gynx)), Aesthetics products ( Botox Cosmetic, The Juvederm Collection of Fillers), Neuroscience products( Botox Therapeutic, Vraylar (cariprazine), Duopa and Duodopa (carbidopa and levodopa), Ubrelvy (ubrogepant), Qulipta (atogepant)), Eye care products (Ozurdex (dexamethasone intravitreal implant), Lumigan (bimatoprost ophthalmic solution), Alphagan (brimonidine tartrate ophthalmic solution), Restasis)) and other key products ( Mavyret (glecaprevir/pibrentasvir), Creon (pancrelipase), Lupron (leuprolide acetate), Linzess (linacloti de), Synthroid (levothyroxine sodium tablets, USP)).

Financially, in 2024, AbbVie successfully earned total revenues of USD 56.3 billion with a net income of USD 4.28 billion. In terms of financial position, AbbVie has total assets of USD 135.1 billion and total liabilities of around USD 131.7 billion.         

 

9. Abbott Laboratories

Abbott Laboratories is a medical and healthcare equipment corporation headquartered in Abbott Park, Illinois, United States. Based on its history, this corporation was founded by a doctor named Wallace Calvin Abbott in 1888 and as of 2023, Abbot employed 114 thousand people.

Commonly, with more than 135 years of experience, Abbot laboratories has some medicine products. These are Creon, Duspatal and Dicetel, Heptral, Transmetil, and Samyr, Duphalac, Duphaston, Femoston, Lipanthyl and TriCor, Teveten and Teveten Plus, Physiotens, Synthroid, Serc, Brufen, Sevedol, Klacid, Claribid, Klaricid, and Influvac.

Financially, according to the annual report in 2024, Abbott Laboratories successfully earned total revenues of USD 41.9 billion with a net profit of USD 13.4 billion. In terms of financial position, Abbott Laboratories has total assets of around USD 81.4 billion and total liabilities of around USD 33.5 billion.  

 

10.AstraZeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology corporation headquartered at the Cambridge Biomedical Campus in Cambridge, England. Perhaps, one of the most popular products is the Oxford-AstraZeneca COVID-19 vaccine, which has been widely marketed in various countries around the world. The foundation of this corporation was in 1999 through the merger of Astra AB of Sweden and the Zeneca Group of the UK. Financially, in 2024, this corporation earned total revenues of USD 54 billion with a net income of USD 7 billion. In terms of financial position, total assets of AstraZeneca around USD 104 billion and total liabilities of around USD 63.1 billion.   

 

Commonly, AstraZeneca focussed on Oncology and BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease. On Oncology, AstraZeneca has some medicine products, namely Tagrisso (osimertinib), Imfinzi (durvalumab), Lynparza (olaparib), Calquence (acalabrutinib), Enhertu (trastuzumab deruxtecan), Orpathys (savolitinib), Truqap (capivasertib), Zoladex (goserelin acetate implant), Faslodex (fulvestrant). Meanwhile in Cardiovascular, Renal & Metabolism, AstraZeneca has some medicine products, namely Farxiga/Forxiga (dapagliflozin), Brilinta/Brilique (ticagrelor), Lokelma (sodium zirconium cyclosilicate), Roxadustat, Andexxa/Ondexxya (andexanet alfa), Crestor (rosuvastatin calcium), Seloken/Toprol-XL (metoprolol succinate), Onglyza family, (exenatide, Qtern, Symlin, Atacand and other established brands), Bydureon (exenatide XR injectable suspension).

In Respiratory & Immunology, AstraZeneca has medicine products i.e. Symbicort (budesonide/ formoterol), Fazenda (benralizumab), Breztri/Trixeo (budesonide/ glycopyrrolate/ formoterol), Tezspire (tezepelumab), Saphnelo (anifrolumab), Pulmicort (budesonide), Bevespi (glycopyrrolate/formoterol), Daliresp/Daxas (roflumilast). Furthermore, in Vaccines & Immune Therapies, the products of AstraZeneca are COVID-19 mAbs (tixagevimab and cilgavimab), Beyfortus (nirsevimab), Vaxzevria (ChAdOx1-S [Recombinant]), Synagis (palivizumab), Fluenz Tetra/FluMist Quadrivalent (live attenuated influenza vaccine). In addition of Rare Disease, the products are Soliris (eculizumab), Ultomiris (ravulizumab), Strensiq (asfotase alfa), Koselugo (selumetinib), Kanuma (sebelipase alfa).

 

11. Bristol Myers Squibb

The Bristol Myers Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York. Operationally, this corporation has Headquartered in Princeton, New Jersey. To date Bristol Myers Squibb has manufacturing operations in the U.S., Puerto Rico, Switzerland, Ireland, and the Netherlands. Meanwhile, Some of the Bristol Myers Squibb products are In-Line Products (Eliquis Eliquis (apixaban), Opdivo (nivolumab), Orencia (abatacept), Pomalyst /ImnovidPomalyst/Imnovid (pomalidomide), Yervoy (ipilimumab),  Sprycel (dasatinib)), New Product Portfolio  (Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Abecma (idecabtagene vicleucel),  Zeposia (ozanimod), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten).

In the year 2024, Bristol Myers Squibb had total assets of USD 92.6 billion with the liabilities around USD 76.2 billion. According to business performance, Bristol Myers Squibb successfully generated revenue of USD 48.3 billion but suffered net loss around USD -8.9 billion.

 

12. Takeda Pharmaceuticals

Historically, the journey of Takeda pharmaceutical was started in 1781 with the initiative of Chobei Takeda who started a business selling traditional Japanese and Chinese medicines in Doshomachi, Osaka. Along with business development, Takeda pharmaceuticals have presence in approximately 80 countries, with leading positions in Japan and the U.S and more than 25 manufacturing sites. Operationally, Takeda Pharmaceuticals still has its headquarters in Tokyo, Japan. Based on the products, Some of the Takeda pharmaceuticals products are Entyvio, Alofisel, TAKHZRO, Livtencity, Cuvitru, Flexbumin, Alunbrig, EXKIVITY, Qdenga, spikevax, and others.

Financially in 2024, according to a financial report, Tekeda Pharmaceuticals has total assets of JPY 14,248 billion or equivalent with USD 99.7 billion. In Business performance, Takeda generated total revenue of JPY 4,581 billion or equivalent to USD 32 billion and successfully gained net income of JPY 107 billion or equivalent to USD 0.75 billion.

 

13. Eli Lilly

Historically, Eli Lilly was founded by Colonel Eli Lilly in 1876 and   has headquartered in Indianapolis, Indiana. Based on products, some of the Eli Lilly products are Diabetes, Obesity and Other Cardiometabolic (Basaglar, Humalog, Insulin Lispro, Humulin, Jardiance, Mounjaro, Trulicity), Oncology products ( Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyr), Immunology products (Ebglyss, Olumiant, Omvoh, Taltz), Neuroscience (Cyambalta, Emgality).

Financially, according to its annual report in 2024, Eli Lilly has total assets around USD 78.7 billion with total liabilities of around USD 64.4 billion. In terms of business performance in 2024, Eli Lilly generated total revenue of USD 45 billion and gained net income of USD 10.5 billion.

 

14. Novo Nordisk

 

Novo Nordisk is a Danish multinational pharmaceutical corporation which was founded on December 21st, 1923. Operationally, this corporation has a main office in Bagsværd, Denmark. As of 2023, Novo Nordisk employed more than 64 thousand people with 5 R&D Facilities in 5 different countries.

As of business development, Novo Nordisk has some medicine products in Obesity medications (Saxenda and Wegovy), Diabetes medications (Tresiba, Xultophy,levemir, Insulatard, Actrapid, Mixtard, NovoMix, Ryzodeg, Rybelsus, Victoza, Ozempic, Fiasp,Novorapid, GlucaGen) Haemophilia medications (NovoSeven, NovoEight, Refixia, Esperoct) , Growth disorder medications (Norditropin and Sogroya), Hormone replacement therapy (vagifem, Activelle, Kliogest, Novofem, and others).

Financially, according to the Annual Report in 2024, Novo Nordisk has total assets around DKK 465 billion or equivalent with USD 69.7 billion with total liabilities of around DKK 322 billion or equivalent USD 48.3 billion. Based on performance in 2024, Novo Nordisk generated total revenue of DKK 290 billion or equivalent to USD 43.5 billion and gained net income of DKK 100 billion or equivalent to USD 15 billion.

 

15. Amgen

Amgen is an American-based pharmaceutical corporation which was incorporated in California in 1980 and became a Delaware corporation in 1987. As of business development, Amgen has a presence in approximately 100 countries worldwide. Commonly, Amgen has some medicine products including Prolia, ENBREL, Otezla XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, KRYSTEXXA.

In the financial positions and business performance of 2024, Amgen had total assets around USD 91.8 billion with total liabilities around USD 85.9 billion. According to business performance in 2024, Amgen successfully generated total revenue of USD 33.4 billion with net income around USD 4 billion.

 

16. Bayer    

Bayer AG is a global pharmaceutical corporation founded by Friedrich Bayer and Johann Friedrich Weskott in August 1863. As of 2024, Bayer has employed 94,081 people. Along with business development,  in the pharmaceutical products, Bayer AG has Bayer AG has research and development sites in Berlin (Germany), Whippany (United States), Wuppertal (Germany) and production sites of its pharmaceutical products located in Bergkamen (Germany), Berlin (Germany), and Leverkusen (Germany). Furthermore, some of well-known pharmaceutical brands from Bayer are Xarelto™, Eylea™, Nubeqa™, Mirena™/Kyleena™/Jaydess™, Adempas™, Kogenate™/Kovaltry™/Jivi™, YAZ™/Yasmin™/Yasminelle™, Aspirin™ Cardio, CT Fluid Delivery, Ultravist™, Adalat™, Kerendia™, Stivarga™, Gadovist™ product family, Betaferon™/Betaseron™.

Financially, in 2024, according to the annual report of 2024, Bayer AG has total assets of around EUR 110.8 billion or equivalent to USD 123 billion with total liabilities of around EUR 78.7 billion or equivalent to USD 87.3 billion. In terms of business performance in 2024, Bayer AG successfully gained total revenue of EUR 46.6 billion or equivalent to USD 51.7 billion but suffered net loss of around EUR -2.5 billion or equivalent to USD -2.7 billion.

 

17. Gilead Sciences         

Gilead Sciences, Inc is an American biopharmaceutical corporation headquartered in Foster City, California originally founded by Michael L. Riordan. Gilead has operated in 35 countries worldwide and provided medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, coronavirus disease (“COVID-19”), cancer and inflammation. Furthermore, some of medicinal brands from Gilead sciences are HIV treatment (Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Symtuza, Truvada, Stribild), Liver Disease treatment (Epclusa, Vemlidy, Harvoni, Viread, Livdelzi (seladelpar)), COVID-19 (Veklury (remdesivir)), Cell Therapy treatment (Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel).

Financially, according to the annual report of 2024, Gilead Sciences has total assets of around USD 58.9 billion with total liabilities of around USD 39.7 billion. Furthermore, in terms of business performance in 2024, Gilead Sciences successfully gained total revenue of around USD 28.7 billion and net income of around USD 0.48 billion.

 

 

The Summary of 17 World’s Biggest Pharmaceutical Corporations Based on Total Assets in 2024

  

 

The Summary of 17 World’s Biggest Pharmaceutical Corporations Based on Net Income in 2024

  

---

Bibliography of 17 world’s Biggest Pharmaceutical Corporations in 2024

---

 

Novo Nordisk. 2025. Annual Report 2024. Accessed via https://www.novonordisk.com/investors/annual-report.html on June 1st, 2025.

 

Johnson& Johnson. 2025. Annual Report 2024. Accessed via https://www.jnj.com/corporate-reports  on June 1st, 2025.

 

Abbott Laboratories. 2025. Annual Report 2024. Accessed via https://www.abbottinvestor.com/financials/annual-reports/ on June 1st, 2025.

 

Novartis. 2025. Annual Report 2024. Accessed via https://www.novartis.com/investors/financial-data/annual-results on June 1st, 2025.

 

Hoffman-La Roche. 2025. Annual Report 2024. Accessed via https://www.roche.com/investors/annualreport24 on June 1st, 2025.

 

Eli Lily. 2025. Annual Report 2024. Accessed via https://investor.lilly.com/financial-information/annual-reports on June 1st, 2025.

 

Pfizer. 2025. Annual Report 2024. Accessed via https://investors.pfizer.com/Investors/Financials/Annual-Reports/default.aspx on June 1st, 2025.

 

Astrazeneca. 2025. Annual Report 2024. Accessed via https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2024.html on June 1st, 2025.

 

Sanofi. 2025. Annual Report 2024. Accessed via https://www.sanofi.com/en/india/consumer-healthcare/investors/annual-reports on June 1st, 2025.

 

AbbVie. 2025. Annual Report 2024. Accessed via https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2024-financial on June 1st, 2025.

 

Amgen Inc. 2025. Annual Report 2024. Accessed via https://investors.amgen.com/financials/annual-reports on June 1st, 2025.

 

GlaxoSmithKline. 2025. Annual Report 2024. Accessed via https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2024/   on June 1st, 2025.

 

Merck & co. 2025. Annual Report 2024. Accessed via https://www.merckgroup.com/en/annualreport/2024/   on June 1st, 2025.

 

Takeda Pharmaceuticals. 2025. Annual Report 2024. Accessed via https://www.takeda.com/investors/annual-integrated-report/   on June 1st, 2025.

 

Gilead Sciences. 2025. Annual Report 2024. Accessed via https://investors.gilead.com/overview/default.aspx  on June 1st, 2025.

 

Bayer. 2025. Annual Report 2024. Accessed via https://www.bayer.com/en/investors/integrated-annual-reports on June 1st, 2025.

 

Bristol Myers Squibb. 2025. Annual Report 2024. Accessed via https://annual-report.bms.com/ on June 1st, 2025.

 

Location:

Share :